Humanetics Corp.

Executive Summary

Humanetics Corporation is a privately held, advanced clinical-stage pharmaceutical company based in Minneapolis, Minnesota, focused on developing novel drugs to protect against and treat bodily harm from radiation, chemical agents, and biological threats. Founded in 1988, the company's lead asset, BIO 300, is a small molecule radiation modulator originally discovered by the U.S. Department of Defense. BIO 300 is being developed for acute radiation syndrome (ARS) and other radiation-related indications, with the potential to serve both military and civilian populations in scenarios of radiological exposure. The company has progressed to Phase 2 clinical trials, positioning it as a key player in the medical countermeasures space. Humanetics benefits from strong government interest and funding, given its focus on national security and public health preparedness. The company's private status allows for a long-term strategic approach, but also means limited public information on financials and operational milestones. Near-term value inflection points center on advancing BIO 300 through clinical development and securing additional government contracts or partnerships. Success in Phase 2 could lead to accelerated development pathways, including potential FDA approval under the Animal Rule, given the ethical challenges of efficacy trials in humans for radiation countermeasures.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Clinical Trial Results for BIO 300 in Acute Radiation Syndrome60% success
• Q3 2026Government Contract Award (e.g., BARDA or DoD) for Development Funding50% success
• Q1 2027Strategic Partnership or Licensing Deal for Commercialization40% success